Overview

A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma

Status:
Completed
Trial end date:
2020-03-27
Target enrollment:
Participant gender:
Summary
A clinical study of safety and efficacy of treatment with Nivolumab and Bendamustine (NB) in patients with relapsed/refractory Hodgkin's lymphoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
St. Petersburg State Pavlov Medical University
Treatments:
Antibodies, Monoclonal
Bendamustine Hydrochloride
Nivolumab